Lisata Therapeutics

Company

Lisata Therapeutics develops one asset, in phase 2 (MAR002 in acromegaly). Mostly other acting on Insulin/IGF-1 signalling and IGF1.

1
Asset
Furthest stage
Phase 2
1
Trial
2
Signals

Pipeline

1

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials1
  • People1
  • Signals2
  • Similar companies6

Intelligence